Serenoa

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform

Zhongbao Zhou - One of the best experts on this subject based on the ideXlab platform.

  • comparison of Serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia a systematic review and meta analysis
    American Journal of Men's Health, 2020
    Co-Authors: Shaoxia Yu, Zhongbao Zhou, Qian Li
    Abstract:

    Studies reported that Serenoa repens was effective in relieving lower urinary tract symptoms (LUTS). This article carried out a systematic review and meta-analysis to compare Serenoa repens with ta...

  • comparison of Serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia a systematic review and meta analysis
    American Journal of Men's Health, 2020
    Co-Authors: Zhongbao Zhou, Tong Cai, Yuanshan Cui, Zhenli Gao
    Abstract:

    Studies reported that Serenoa repens was effective in relieving lower urinary tract symptoms (LUTS). This article carried out a systematic review and meta-analysis to compare Serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia (BPH) after at least 6-month treatment cycle. Four studies involving 1,080 patients (543 in the Serenoa repens group and 537 in the tamsulosin group) were included in the meta-analysis. The results were as follows: compared with tamsulosin, Serenoa repens had a same effect in treating BPH in terms of International Prostate Symptom Score (IPSS) (mean difference [MD] 0.63, 95% confidence interval [CI] [-0.33, 1.59], p = 0.20), quality of life (QoL) (MD 1.51, 95% CI [-1.51, 4.52], p = 0.33), maximum flow rate (Qmax) (MD 0.27, 95% CI [-0.15, 0.68], p = 0.21), postvoid residual volume (PVR) (MD -4.23, 95% CI [-22.97, 14.44], p = 0.65), prostate-specific antigen (PSA) (MD 0.46, 95% CI [-0.06, 0.97], p = 0.08) with the exception of prostate volume (PV) (MD -0.29, 95% CI [-0.41, -0.17], p < 0.00001). For side effects, Serenoa repens was well tolerated compared with tamsulosin especially in ejaculation disorders (odds ratio [OR] = 12.56, 95% CI [3.83, 41.18], p < 0.0001) and decreased libido (OR = 5.40; 95% CI [1.17, 24.87]; p = 0.03). This study indicated that Serenoa repens had the same effect in treating BPH compared with tamsulosin in terms of IPSS, QoL, and PVR after at least 6-month treatment cycle, however, the latter had a greater improvement in PV compared with the former. And Serenoa repens did not increase the risk of adverse events especially with respect to ejaculation disorders and libido decrease.

Giuseppe Morgia - One of the best experts on this subject based on the ideXlab platform.

  • Serenoa repens lycopene and selenium a triple therapeutic approach to manage benign prostatic hyperplasia
    Current Medicinal Chemistry, 2013
    Co-Authors: Letteria Minutoli, Alessandra Bitto, Natasha Irrera, Herbert Marini, Giuseppe Morgia, Francesco Squadrito, Annamaria Passantino, Domenica Altavilla
    Abstract:

    Benign prostatic hyperplasia (BPH) is a major health concern that is likely to have an increasing impact in line with the gradual aging of the population. BPH is characterized by smooth muscle and epithelial proliferation primarily within the prostatic transition zone that can cause a variety of problems for patients, the most frequent are the lower urinary tract symptoms. BPH is thought to involve in disruption of dihydrotestosterone (DHT)-supported homeostasis between cell proliferation and cell death, and, as a result, proliferative processes predominate and apoptotic processes are inhibited. Phytotherapeutic supplements, mainly based on Saw Palmetto-derived Serenoa Repens (SeR), are numerous and used frequently. Serenoa Repens reduces inflammation and decreases in vivo the androgenic support to prostatic cell growth. Furthermore, SeR stimulates the apoptotic machinery; however, data supporting efficacy is limited, making treatment recommendations difficult. Besides SeR, selenium (Se), an essential trace element mainly functioning through selenoproteins and able to promote an optimal antioxidant/oxidant balance, and lycopene (Ly), a dietary carotenoid synthesized by plants, fruits, and microorganisms with a strong antioxidant activity, has been shown to exert beneficial effects in prostate disease. SeR is frequently associated with Ly and Se, in order to increase its therapeutic activity in benign prostatic hyperplasia (BPH). It has been shown that the Ly-Se-SeR association has a greater and enhanced antiinflammatory activity that might be of particular interest in the treatment of BPH. The Ly-Se-SeR association is also more effective than SeR alone in reducing prostate weight and hyperplasia, in augmenting the pro-apoptotic Bax and caspase-9 and blunting the anti-apoptotic Bcl-2 mRNA. In addition, Ly-Se-SeR more efficiently suppresses the EGF and Vascular Endothelial Growth Factor (VEGF) expressions in hyperplastic prostates. Therefore, SeR particularly when combined with Se and Ly may have a greater potential for the management of benign prostate hyperplasia.

  • the combination of Serenoa repens selenium and lycopene is more effective than Serenoa repens alone to prevent hormone dependent prostatic growth
    The Journal of Urology, 2011
    Co-Authors: Domenica Altavilla, Alessandra Bitto, Francesca Polito, Natasha Irrera, Herbert Marini, Vincenzo Favilla, Salvatore Arena, Giuseppe Morgia, Francesco Squadrito, Letteria Minutoli
    Abstract:

    Purpose: Serenoa repens is frequently combined with other natural compounds, such as the carotenoid lycopene and the essential trace element Se, to increase its therapeutic activity in benign prostatic hyperplasia. We noted that the lycopene-Se-Serenoa repens combination has greater, enhanced anti-inflammatory activity, which might be of particular interest for benign prostatic hyperplasia treatment. Testosterone administration in rats is a suitable tool for investigating hormone dependent benign prostatic hyperplasia. We performed a comparison experiment between Serenoa repens and the lycopene-Se-Serenoa repens combination on prostate growth induced in rats by testosterone administration.Materials and Methods: Rats were treated daily with testosterone propionate (3 mg/kg subcutaneously) or its vehicle for 14 days. Testosterone administered animals were randomized to receive vehicle, Serenoa repens (25 mg/kg subcutaneously) or the combination of lycopene (3 mg/kg subcutaneously), Se (3 mg/kg subcutaneousl...

  • treatment of chronic prostatitis chronic pelvic pain syndrome category iiia with Serenoa repens plus selenium and lycopene profluss versus s repens alone an italian randomized multicenter controlled study
    Urologia Internationalis, 2010
    Co-Authors: Giuseppe Morgia, Giuseppe Mucciardi, Alessandro Gali, Massimo Madonia, F Marchese, G Romano, Giulio Bonvissuto, Tommaso Castelli, A Di Benedetto, Luciano Macchione
    Abstract:

    Objectives: To evaluate the efficacy and safety of Serenoa repens + selenium and lycopene (Profluss®) versus S. repens alone for the treatment

Groupe De Lessai Ocos - One of the best experts on this subject based on the ideXlab platform.

  • tamsulosine avec ou sans Serenoa repens dans l hypertrophie benigne de la prostate l essai ocos
    Progres En Urologie, 2002
    Co-Authors: Pascal Glemain, T Billebaud, Raphael Muszynski, Gerard Loeb, Christian Coulange, Bernard Gattegno, Groupe De Lessai Ocos
    Abstract:

    But : Dans le traitement des symptomes de l'hypertrophie benigne de la prostate (HBP), une reference medicale (RMO) s'oppose aux associations medicamenteuses car leur utilite n'est pas demontree. L'essai OCOS a donc compare l'une des associations possibles (tamsulosine-Serenoa repens) a la tamsulosine seule, recherchant une difference d'efficacite et evaluant leur tolerance clinique chez des patients ayant une HBP symptomatique. Materiel et Methodes :Les patients de cet essai randomise en double insu devaient avoir un IPSS (International Prostate Symptom Score) ≥ 13 et un Qmax entre 7 et 15 mL/s. La tamsulosine (0,4 mg) devait etre administree une fois par jour pendant 52 semaines, avec, deux fois par jour, un placebo (TAM) ou Serenoa repens 160 mg (TAM+SR). Resultats: 352 patients ont ete recrutes par 47 centres; 329 (âge moyen: 65 ans) ont ete randomises: 161 dans le groupe TAM, 168 dans le groupe TAM+SR. Aucune difference statistiquement significative entre les groupes n'a ete observee, ni pour le critere principal [la variation de l'IPSS total entre la valeur de base et la derniere evaluation (TAM: -5,2; TAM+SR: -6,0; p = 0,286)], ni pour les criteres secondaires [variations des scores d'evacuation (p = 0,239) et de remplissage (p = 0,475) de l'IPSS, du Qmax (p = 0,564), pourcentages de repondeurs selon l'IPSS (p = 0,361), amelioration de la qualite de vie (IPSS-QoL: p = 0,091; UROLIFE© BPH QoL9: p = 0,442), tolerance]. Conclusion: L'addition de Serenoa repens a la tamsulosine n'a apporte aucun benefice significatif aux patients: l'essai OCOS ne remet pas en cause la RMO applicable au traitement de l'HBP.

  • tamsulosine avec ou sans Serenoa repens dans l hypertrophie benigne de la prostate l essai ocos
    Progres En Urologie, 2002
    Co-Authors: Pascal Glemain, T Billebaud, Raphael Muszynski, Gerard Loeb, Christian Coulange, Bernard Gattegno, Groupe De Lessai Ocos
    Abstract:

    But : Dans le traitement des symptomes de l'hypertrophie benigne de la prostate (HBP), une reference medicale (RMO) s'oppose aux associations medicamenteuses car leur utilite n'est pas demontree. L'essai OCOS a donc compare l'une des associations possibles (tamsulosine-Serenoa repens) a la tamsulosine seule, recherchant une difference d'efficacite et evaluant leur tolerance clinique chez des patients ayant une HBP symptomatique. Materiel et Methodes :Les patients de cet essai randomise en double insu devaient avoir un IPSS (International Prostate Symptom Score) ≥ 13 et un Qmax entre 7 et 15 mL/s. La tamsulosine (0,4 mg) devait etre administree une fois par jour pendant 52 semaines, avec, deux fois par jour, un placebo (TAM) ou Serenoa repens 160 mg (TAM+SR). Resultats: 352 patients ont ete recrutes par 47 centres; 329 (âge moyen: 65 ans) ont ete randomises: 161 dans le groupe TAM, 168 dans le groupe TAM+SR. Aucune difference statistiquement significative entre les groupes n'a ete observee, ni pour le critere principal [la variation de l'IPSS total entre la valeur de base et la derniere evaluation (TAM: -5,2; TAM+SR: -6,0; p = 0,286)], ni pour les criteres secondaires [variations des scores d'evacuation (p = 0,239) et de remplissage (p = 0,475) de l'IPSS, du Qmax (p = 0,564), pourcentages de repondeurs selon l'IPSS (p = 0,361), amelioration de la qualite de vie (IPSS-QoL: p = 0,091; UROLIFE© BPH QoL9: p = 0,442), tolerance]. Conclusion: L'addition de Serenoa repens a la tamsulosine n'a apporte aucun benefice significatif aux patients: l'essai OCOS ne remet pas en cause la RMO applicable au traitement de l'HBP.

  • tamsulosin with or without Serenoa repens in benign prostatic hyperplasia the ocos trial
    Progres En Urologie, 2002
    Co-Authors: Pascal Glemain, T Billebaud, Raphael Muszynski, Gerard Loeb, Christian Coulange, Bernard Gattegno, Groupe De Lessai Ocos
    Abstract:

    But : Dans le traitement des symptomes de l'hypertrophie benigne de la prostate (HBP), une reference medicale (RMO) s'oppose aux associations medicamenteuses car leur utilite n'est pas demontree. L'essai OCOS a donc compare l'une des associations possibles (tamsulosine-Serenoa repens) a la tamsulosine seule, recherchant une difference d'efficacite et evaluant leur tolerance clinique chez des patients ayant une HBP symptomatique. Materiel et Methodes :Les patients de cet essai randomise en double insu devaient avoir un IPSS (International Prostate Symptom Score) ≥ 13 et un Qmax entre 7 et 15 mL/s. La tamsulosine (0,4 mg) devait etre administree une fois par jour pendant 52 semaines, avec, deux fois par jour, un placebo (TAM) ou Serenoa repens 160 mg (TAM+SR). Resultats: 352 patients ont ete recrutes par 47 centres; 329 (âge moyen: 65 ans) ont ete randomises: 161 dans le groupe TAM, 168 dans le groupe TAM+SR. Aucune difference statistiquement significative entre les groupes n'a ete observee, ni pour le critere principal [la variation de l'IPSS total entre la valeur de base et la derniere evaluation (TAM: -5,2; TAM+SR: -6,0; p = 0,286)], ni pour les criteres secondaires [variations des scores d'evacuation (p = 0,239) et de remplissage (p = 0,475) de l'IPSS, du Qmax (p = 0,564), pourcentages de repondeurs selon l'IPSS (p = 0,361), amelioration de la qualite de vie (IPSS-QoL: p = 0,091; UROLIFE© BPH QoL9: p = 0,442), tolerance]. Conclusion: L'addition de Serenoa repens a la tamsulosine n'a apporte aucun benefice significatif aux patients: l'essai OCOS ne remet pas en cause la RMO applicable au traitement de l'HBP.

Domenica Altavilla - One of the best experts on this subject based on the ideXlab platform.

  • Serenoa repens lycopene and selenium a triple therapeutic approach to manage benign prostatic hyperplasia
    Current Medicinal Chemistry, 2013
    Co-Authors: Letteria Minutoli, Alessandra Bitto, Natasha Irrera, Herbert Marini, Giuseppe Morgia, Francesco Squadrito, Annamaria Passantino, Domenica Altavilla
    Abstract:

    Benign prostatic hyperplasia (BPH) is a major health concern that is likely to have an increasing impact in line with the gradual aging of the population. BPH is characterized by smooth muscle and epithelial proliferation primarily within the prostatic transition zone that can cause a variety of problems for patients, the most frequent are the lower urinary tract symptoms. BPH is thought to involve in disruption of dihydrotestosterone (DHT)-supported homeostasis between cell proliferation and cell death, and, as a result, proliferative processes predominate and apoptotic processes are inhibited. Phytotherapeutic supplements, mainly based on Saw Palmetto-derived Serenoa Repens (SeR), are numerous and used frequently. Serenoa Repens reduces inflammation and decreases in vivo the androgenic support to prostatic cell growth. Furthermore, SeR stimulates the apoptotic machinery; however, data supporting efficacy is limited, making treatment recommendations difficult. Besides SeR, selenium (Se), an essential trace element mainly functioning through selenoproteins and able to promote an optimal antioxidant/oxidant balance, and lycopene (Ly), a dietary carotenoid synthesized by plants, fruits, and microorganisms with a strong antioxidant activity, has been shown to exert beneficial effects in prostate disease. SeR is frequently associated with Ly and Se, in order to increase its therapeutic activity in benign prostatic hyperplasia (BPH). It has been shown that the Ly-Se-SeR association has a greater and enhanced antiinflammatory activity that might be of particular interest in the treatment of BPH. The Ly-Se-SeR association is also more effective than SeR alone in reducing prostate weight and hyperplasia, in augmenting the pro-apoptotic Bax and caspase-9 and blunting the anti-apoptotic Bcl-2 mRNA. In addition, Ly-Se-SeR more efficiently suppresses the EGF and Vascular Endothelial Growth Factor (VEGF) expressions in hyperplastic prostates. Therefore, SeR particularly when combined with Se and Ly may have a greater potential for the management of benign prostate hyperplasia.

  • the combination of Serenoa repens selenium and lycopene is more effective than Serenoa repens alone to prevent hormone dependent prostatic growth
    The Journal of Urology, 2011
    Co-Authors: Domenica Altavilla, Alessandra Bitto, Francesca Polito, Natasha Irrera, Herbert Marini, Vincenzo Favilla, Salvatore Arena, Giuseppe Morgia, Francesco Squadrito, Letteria Minutoli
    Abstract:

    Purpose: Serenoa repens is frequently combined with other natural compounds, such as the carotenoid lycopene and the essential trace element Se, to increase its therapeutic activity in benign prostatic hyperplasia. We noted that the lycopene-Se-Serenoa repens combination has greater, enhanced anti-inflammatory activity, which might be of particular interest for benign prostatic hyperplasia treatment. Testosterone administration in rats is a suitable tool for investigating hormone dependent benign prostatic hyperplasia. We performed a comparison experiment between Serenoa repens and the lycopene-Se-Serenoa repens combination on prostate growth induced in rats by testosterone administration.Materials and Methods: Rats were treated daily with testosterone propionate (3 mg/kg subcutaneously) or its vehicle for 14 days. Testosterone administered animals were randomized to receive vehicle, Serenoa repens (25 mg/kg subcutaneously) or the combination of lycopene (3 mg/kg subcutaneously), Se (3 mg/kg subcutaneousl...

Letteria Minutoli - One of the best experts on this subject based on the ideXlab platform.

  • Serenoa repens lycopene and selenium a triple therapeutic approach to manage benign prostatic hyperplasia
    Current Medicinal Chemistry, 2013
    Co-Authors: Letteria Minutoli, Alessandra Bitto, Natasha Irrera, Herbert Marini, Giuseppe Morgia, Francesco Squadrito, Annamaria Passantino, Domenica Altavilla
    Abstract:

    Benign prostatic hyperplasia (BPH) is a major health concern that is likely to have an increasing impact in line with the gradual aging of the population. BPH is characterized by smooth muscle and epithelial proliferation primarily within the prostatic transition zone that can cause a variety of problems for patients, the most frequent are the lower urinary tract symptoms. BPH is thought to involve in disruption of dihydrotestosterone (DHT)-supported homeostasis between cell proliferation and cell death, and, as a result, proliferative processes predominate and apoptotic processes are inhibited. Phytotherapeutic supplements, mainly based on Saw Palmetto-derived Serenoa Repens (SeR), are numerous and used frequently. Serenoa Repens reduces inflammation and decreases in vivo the androgenic support to prostatic cell growth. Furthermore, SeR stimulates the apoptotic machinery; however, data supporting efficacy is limited, making treatment recommendations difficult. Besides SeR, selenium (Se), an essential trace element mainly functioning through selenoproteins and able to promote an optimal antioxidant/oxidant balance, and lycopene (Ly), a dietary carotenoid synthesized by plants, fruits, and microorganisms with a strong antioxidant activity, has been shown to exert beneficial effects in prostate disease. SeR is frequently associated with Ly and Se, in order to increase its therapeutic activity in benign prostatic hyperplasia (BPH). It has been shown that the Ly-Se-SeR association has a greater and enhanced antiinflammatory activity that might be of particular interest in the treatment of BPH. The Ly-Se-SeR association is also more effective than SeR alone in reducing prostate weight and hyperplasia, in augmenting the pro-apoptotic Bax and caspase-9 and blunting the anti-apoptotic Bcl-2 mRNA. In addition, Ly-Se-SeR more efficiently suppresses the EGF and Vascular Endothelial Growth Factor (VEGF) expressions in hyperplastic prostates. Therefore, SeR particularly when combined with Se and Ly may have a greater potential for the management of benign prostate hyperplasia.

  • the combination of Serenoa repens selenium and lycopene is more effective than Serenoa repens alone to prevent hormone dependent prostatic growth
    The Journal of Urology, 2011
    Co-Authors: Domenica Altavilla, Alessandra Bitto, Francesca Polito, Natasha Irrera, Herbert Marini, Vincenzo Favilla, Salvatore Arena, Giuseppe Morgia, Francesco Squadrito, Letteria Minutoli
    Abstract:

    Purpose: Serenoa repens is frequently combined with other natural compounds, such as the carotenoid lycopene and the essential trace element Se, to increase its therapeutic activity in benign prostatic hyperplasia. We noted that the lycopene-Se-Serenoa repens combination has greater, enhanced anti-inflammatory activity, which might be of particular interest for benign prostatic hyperplasia treatment. Testosterone administration in rats is a suitable tool for investigating hormone dependent benign prostatic hyperplasia. We performed a comparison experiment between Serenoa repens and the lycopene-Se-Serenoa repens combination on prostate growth induced in rats by testosterone administration.Materials and Methods: Rats were treated daily with testosterone propionate (3 mg/kg subcutaneously) or its vehicle for 14 days. Testosterone administered animals were randomized to receive vehicle, Serenoa repens (25 mg/kg subcutaneously) or the combination of lycopene (3 mg/kg subcutaneously), Se (3 mg/kg subcutaneousl...

Related terms

Serenoa - 15 days free trial to Access Experts & Abstracts